Recent news on Engerix-B

'No link' between autism and mercury-containing vaccines  -  May 16, 2007
BiopharmaReporter.com,These include Merck & Co's Recombivax-HB (thimerosal free), GlaxoSmithKline's Engerix-B (trace thimerosal), and Aventis-Pasteur's Tripedia (trace

WeissComm Partners Announces Several New Hires to Strengthen and ...  -  Apr 23, 2007
PR Newswire (press release),...and several products for GlaxoSmithKline, including Advair(R), for the treatment of asthma and chronic obstructive pulmonary disease, Engerix-B(R),

Accelerated Dosing Schedule Approved for Twinrix® Vaccine for ...  -  Apr 3, 2007
EndoNurse,...compared to separate vaccinations with monovalent hepatitis A vaccine (HAVRIX at 0 and 12 months) and hepatitis B vaccine (ENGERIX-B at 0, 1, 2,

Vaccine market to top $23B  -  Feb 10, 2007
Monsters and Critics.com,The top-selling hepatitis B vaccine currently is GSK`s Engerix-B. Decision Resources analysts told UPI their analysis indicates influenza, HIV and cancer

Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM ...  -  Dec 21, 2006
PipelineReview.com (press release),Recently reported data from a Phase 3 study show that after three doses, HEPLISAV provided seroprotection to 100% of subjects versus 73.1% for Engerix-B (p

Biotech Stocks Day-in-Review: Genentech Buys Altus' Pipeline  -  Dec 21, 2006
Seeking Alpha,The trial will compare a two-dose regimen of the drug to a three-dose regimen of Engerix-B. Dynavax closed unchanged at $9.05.

Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM ...  -  Dec 21, 2006
PipelineReview.com (press release),Recently reported data from a Phase 3 study show that after three doses, HEPLISAV provided seroprotection to 100% of subjects versus 73.1% for Engerix-B (p

Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically ...  -  Nov 29, 2006
PipelineReview.com (press release),Data for the entire study population show that after two doses, HEPLISAV provided 98.5% seroprotection versus Engerix-B's 25%.

Hepatitis B Results Provide Boost To Dynavax's Stock  -  Nov 29, 2006
BioWorld Online,...based company released results from a trial comparing the investigational vaccine to Engerix-B (from GlaxoSmithKline plc) in a difficult-to-immunize

Dynavax shares rocket on Hep B vaccine data  -  Dec 1, 2006
Pharma Times (subscription),...showed that after three doses Heplisav provided seroprotection to 100% of subjects, compared to 73.1% in the group given GlaxoSmithKline's Engerix-B.

Dynavax shares rocket on hepatitis B vaccine data  -  Nov 29, 2006
MarketWatchEngerix-B vaccine, which was found to protect 73.1% of such people. In those ranging from 56 to 70 years of age, Heplisav's rate of protection was

Vaccine tests for hepatitis B are promising  -  Nov 29, 2006
San Francisco Chronicle,Heplisav not only immunized a larger percentage of older adults than Engerix-B, but also generated a higher level of antibodies measured four weeks after

UPDATE 1-Dynavax says hepatitis B vaccine bests rival in trial  -  Nov 28, 2006
ReutersAfter two doses, Heplisav protected 98.5 percent of those treated, compared with 25 percent for Engerix-B, the company said.

Dynavax stock rises after trial shows Hepatitis B vaccine effective  -  Nov 29, 2006
Canada.com,If it reaches market, Heplisav would have two competitors, Engerix-B from London-based GlaxoSmithKline PLC, and Recombivax from Whitehouse Station,

Dynavax says Hep B vaccine meets study goal  -  Nov 28, 2006
Reuters...provided protection against the virus in 100 percent of subjects, compared with 73.1 percent of subjects receiving another vaccine called Engerix-B,

The 5-Sigma Report  -  Dec 5, 2006
Motley FoolWith only two approved vaccines currently available, Engerix-B and Merck's (NYSE: MRK) Recombivax HB, Dynavax could see some serious revenue coming their

Dynavax vaccine superior to GSK rival  -  Nov 29, 2006
Pharmaceutical Business ReviewData for the entire study population show that after two doses, Heplisav provided 98.5% seroprotection versus Engerix-B's 25%.

Wednesday's Early Winners & Losers  -  Nov 29, 2006
TheStreet.comThe study showed that Heplisav provided an average immunity level that was 18.5 times higher than GlaxoSmithKline's Engerix-B vaccine, at least as measured

Dynavax Investors Not Immune to Risk  -  Dec 5, 2006
TheStreet.comThe small-cap drug company compared its experimental vaccine Heplisav to GlaxoSmithKline's (GSK - commentary - Cramer's Take) Engerix-B. In individuals

Winners and Losers - November 27th - December 1st (DVAX, DBRN, MWRK)  -  Dec 1, 2006
Investopedia,...protecting people in the 40 – 70 year old age group against hepatitis B compared to an equivalent vaccine (Engerix-B) produced by GlaxoSmithKline (GSK).

Dynavax: limited potential for Heplisav despite promising data  -  Dec 8, 2006
Pharmaceutical Business ReviewIn November 2006, the company presented data showing that Heplisav provided seroprotection of 100% after three doses, versus 73.1% for Engerix-B,

Biotech Stocks Day-in-Review: Genentech Buys Altus' Pipeline  -  Dec 21, 2006
Seeking Alpha,The trial will compare a two-dose regimen of the drug to a three-dose regimen of Engerix-B. Dynavax closed unchanged at $9.05.

Dynavax Technologies Is Rising On Phase 3 Results  -  Nov 28, 2006
Trading Markets,The results showed that after three doses, HEPLISAV provided seroprotection to 100% of subjects versus 73.1% for Engerix-B. HEPLISAV also provided a level

Dynavax Shares Jump on Positive Hepatitis Study  -  Nov 30, 2006
Seeking Alpha,The study showed a statistically significant advantage of Dynavax's HEPLISAV HEP B vaccine when compared to the conventional vaccine, Engerix-B,

Trial Results Lift Dynavax  -  Nov 28, 2006
TheStreet.com...comparing Heplisav to GlaxoSmithKline's (GSK - commentary - Cramer's Take) Engerix-B vaccine in a difficult-to-immunize population of older adults.

Biotech And Drug Stocks Mix It Up  -  Dec 2, 2006
Forbes,...an HBV vaccine could exceed $500 million, and note the data presented for Heplisav supports its superiority to a prevailing vaccine, GSK's Engerix-B."

Dynavax says hepatitis vaccine does well in test  -  Nov 29, 2006
Bizjournals.com,In some age groups, such as patients 56 to 70, the Dynavax vaccine showed an even greater difference in protection over Engerix-B.

Dynavax Technologies Soared On Positive Phase 3 News  -  Nov 29, 2006
Trading Markets,...significant results in Phase 3 trial, compared to GlaxoSmithKline's Engerix-B vaccine in a difficult-to-immunize population of older adults.

Dynavax says hepatitis vaccine does well in test  -  Nov 28, 2006
San Francisco Business Times,In some age groups, like patients from 56 to 70, the Dynavax vaccine showed an even greater difference in protection over Engerix-B.

Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows 100 ...  -  Dec 5, 2006
PipelineReview.com (press release),Canada and the United States before the year-end, comparing the two-dose regimen against Engerix-B in patients from 11 to 55 years of age.

Dynavax: Heplisav Meets Trial Goal  -  Nov 28, 2006
Houston Chronicle,...hepatitis B vaccine provided total protection against the disease in older patients when compared with rival GlaxoSmithKline PLC's Engerix-B vaccine.

Dynavax Shares Rise as Hepatitis B Shot Beats Glaxo's (Update2)  -  Nov 28, 2006
BloombergTwo doses of Dynavax's Heplisav protected more than 98 percent of patients, compared with 25 percent who were protected by two shots of Glaxo's Engerix-B

Dynavax shares rise on study results  -  Dec 4, 2006
BusinessWeekThe trial will compare the drug with rival GlaxoSmithKline PLC's Engerix-B vaccine and is expected to finish in 2008.

StreetInsider.com After-Hours Movers 11/28  -  Nov 28, 2006
StreetInsider.com (subscription),3 trial comparing HEPLISAV, its hepatitis B virus vaccine, to GlaxoSmithKline's Engerix-B vaccine in a difficult-to-immunize population of older adults.

BUSINESS IN BRIEF  -  Nov 30, 2006
Contra Costa Times,If it reaches market, Heplisav would have two competitors, Engerix-B from London-based GlaxoSmithKline PLC and Recombivax from Whitehouse Station,

Pfizer Up After Move to Cut Staff;  -  Nov 29, 2006
Wall Street Journal (subscription),...from the primary endpoint analysis of a Phase III trial comparing Heplisav, its hepatitis B virus vaccine, to GlaxoSmithKline's Engerix-B vaccine.

Stocks to Watch, Nov. 29: TiVo, Pfizer, Tribune  -  Nov 29, 2006
FOX News...from the primary endpoint analysis of a Phase III trial comparing Heplisav, its hepatitis B virus vaccine, to GlaxoSmithKline's (GSK) Engerix-B vaccine.

Eye On Stocks For Wednesday, Nov. 29, 2006  -  Nov 28, 2006
Forbes,GlaxoSmithKline's (nyse: GSK - news - people ) Engerix-B vaccine. Bear Stearns made the call back on Nov. 17 when it upgraded Dynavax to "outperform.

Aftermarket Movers: Retail Results  -  Nov 28, 2006
Houston Chronicle,Dynavax said the vaccine provided total protection against the disease in older patients, compared with rival GlaxoSmithKline's Engerix-B vaccine.

StreetInsider.com Unusual 11 Mid-Day Movers 11/29/06  -  Nov 29, 2006
StreetInsider.com (subscription),...its hepatitis B virus vaccine, to GlaxoSmithKline's (NYSE: GSK) Engerix-B vaccine in a difficult-to-immunize population of older adults.

STOCKS TO WATCH: STOCKS TO WATCH  -  Nov 29, 2006
Asbury Park Press,...experimental vaccine Heplisav increased protection against the liver disease hepatitis B in fewer doses than GlaxoSmithKline PLC's (GSK LN) Engerix-B.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional